Orphan Drug Approvals — October 13, 2026

Amgen Inc. received an FDA approval for evolocumab (REPATHA), categorized as a label expansion with a bullish signal at 5/10 strength and 5/10 materiality. Indication scope, patient population size, and pricing impact were not disclosed in the approval data.

The approval record is a fallback-type classification with no disclosed indication, label scope, or post-marketing requirements, limiting the ability to verify the durability or breadth of the expansion for evolocumab (REPATHA).

Evolocumab (REPATHA) label expansion from Amgen Inc. could extend the franchise into an additional patient segment, though the size and commercial impact are NOT_DISCLOSED.

The single approval is a label expansion for a PCSK9 inhibitor, which is consistent with continued investment in established cardiovascular franchises rather than new entrant activity. With only one action in the period, this is a single data point and not a sector trend.

{"entity" => "Evolocumab (REPATHA) / Amgen Inc.", "reason" => "Label expansion approval with bullish signal (5/10 strength, 5/10 materiality) but NOT_DISCLOSED peak sales, exclusivity, pricing power, and market position.", "trigger" => "Publication of the full expanded label and Amgen Inc. commercial guidance on the new indication, including any payer coverage decisions"}